Loading...

Primo N Lara

TitleProf
InstitutionUniversity of California Davis
Address
vCardDownload vCard

    Collapse Bibliographic 
    Collapse Publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help.
    List All   |   Timeline
    1. Gandara DR, Riess JW, Lara P. In Search of an Oncogene Driver for Squamous Lung Cancer. JAMA Oncol. 2018 Jun 14. PMID: 29902311.
      View in: PubMed
    2. Ho PY, Duan Z, Batra N, Jilek JL, Tu MJ, Qiu JX, Hu Z, Wun T, Lara P, DeVere White RW, Chen HW, Yu AM. Bioengineered Noncoding RNAs Selectively Change Cellular miRNome Profiles for Cancer Therapy. J Pharmacol Exp Ther. 2018 Jun; 365(3):494-506. PMID: 29602831.
      View in: PubMed
    3. Parikh M, Lara P. Modern Systemic Therapy for Metastatic Renal Cell Carcinoma of the Clear Cell Type. Annu Rev Med. 2018 Jan 29; 69:209-221. PMID: 29144835.
      View in: PubMed
    4. Lara P, Heilmann AM, Elvin JA, Parikh M, de Vere White R, Gandour-Edwards R, Evans CP, Pan CX, Schrock AB, Erlich R, Ross JS, Stephens PJ, McPherson J, Miller VA, Ali SM. TMPRSS2-ERG fusions unexpectedly identified in men initially diagnosed with nonprostatic malignancies. JCO Precis Oncol. 2017; 2017. PMID: 29629426.
      View in: PubMed
    5. Yuh LM, Lara P, Wagenaar RM, Evans CP, Dall'era MA, Cress R, Yap SA. A contemporary population-based study of testicular sex cord stromal tumours: Presentation, treatment patterns, and predictors of outcome. Can Urol Assoc J. 2017 Sep; 11(9):E344-E349. PMID: 29382456.
      View in: PubMed
    6. Lara JD, Brunson A, Riess JW, Kelly K, Lara P, Gandara DR. Clinical predictors of survival in young patients with small cell lung cancer: Results from the California Cancer Registry. Lung Cancer. 2017 Oct; 112:165-168. PMID: 29191590.
      View in: PubMed
    7. Dorff TB, Longmate JA, Pal SK, Stadler WM, Fishman MN, Vaishampayan UN, Rao A, Pinksi JK, Hu JS, Quinn DI, Lara P. Bevacizumab alone or in combination with TRC105 for patients with refractory metastatic renal cell cancer. Cancer. 2017 Dec 01; 123(23):4566-4573. PMID: 28832978.
      View in: PubMed
    8. Sonpavde G, Pond GR, Plets M, Tangen CM, Hussain MHA, Lara P, Goldkorn A, Garzotto MG, Mack PC, Higano CS, Vogelzang NJ, Thompson IM, Twardowski PW, Van Veldhuizen PJ, Agarwal N, Carducci MA, Monk JP, Quinn DI. Validation of the Association of RECIST Changes With Survival in Men With Metastatic Castration-Resistant Prostate Cancer Treated on SWOG Study S0421. Clin Genitourin Cancer. 2017 Dec; 15(6):635-641. PMID: 28579151.
      View in: PubMed
    9. Jian C, Tu MJ, Ho PY, Duan Z, Zhang Q, Qiu JX, DeVere White RW, Wun T, Lara P, Lam KS, Yu AX, Yu AM. Co-targeting of DNA, RNA, and protein molecules provides optimal outcomes for treating osteosarcoma and pulmonary metastasis in spontaneous and experimental metastasis mouse models. Oncotarget. 2017 May 09; 8(19):30742-30755. PMID: 28415566.
      View in: PubMed
    10. Wettersten HI, Aboud OA, Lara P, Weiss RH. Metabolic reprogramming in clear cell renal cell carcinoma. Nat Rev Nephrol. 2017 07; 13(7):410-419. PMID: 28480903.
      View in: PubMed
    11. Wakelee HA, Gettinger S, Engelman J, Jänne PA, West H, Subramaniam DS, Leach J, Wax M, Yaron Y, Miles DR, Lara P. A phase Ib/II study of cabozantinib (XL184) with or without erlotinib in patients with non-small cell lung cancer. Cancer Chemother Pharmacol. 2017 May; 79(5):923-932. PMID: 28352985.
      View in: PubMed
    12. Semrad TJ, Kim EJ, Tanaka MS, Sands J, Roberts C, Burich RA, Li Y, Gandara DR, Lara P, Mack PC. Phase II Study of Dovitinib in Patients Progressing on Anti-Vascular Endothelial Growth Factor Therapy. Cancer Treat Res Commun. 2017; 10:21-26. PMID: 28736761.
      View in: PubMed
    13. Gandara DR, Riess JW, Kelly K, Li T, Mack PC, Lara P. Evolution and Increasing Complexity of the Therapeutic Landscape in Advanced Non-Small-cell Lung Cancer. Clin Lung Cancer. 2017 01; 18(1):1-4. PMID: 28082049.
      View in: PubMed
    14. Lara MS, Holland WS, Chinn D, Burich RA, Lara P, Gandara DR, Kelly K, Mack PC. Preclinical Evaluation of MET Inhibitor INC-280 With or Without the Epidermal Growth Factor Receptor Inhibitor Erlotinib in Non-Small-Cell Lung Cancer. Clin Lung Cancer. 2017 05; 18(3):281-285. PMID: 28038979.
      View in: PubMed
    15. Cho H, Matsumoto S, Fujita Y, Kuroda A, Menju T, Sonobe M, Kondo N, Torii I, Nakano T, Lara P, Gandara DR, Date H, Hasegawa S. Trametinib plus 4-Methylumbelliferone Exhibits Antitumor Effects by ERK Blockade and CD44 Downregulation and Affects PD-1 and PD-L1 in Malignant Pleural Mesothelioma. J Thorac Oncol. 2017 03; 12(3):477-490. PMID: 27867002.
      View in: PubMed
    16. Riess JW, Lara P, Gandara DR. Theory Meets Practice for Immune Checkpoint Blockade in Small-Cell Lung Cancer. J Clin Oncol. 2016 Nov 01; 34(31):3717-3718. PMID: 27601544.
      View in: PubMed
    17. Li T, Piperdi B, Walsh WV, Kim M, Beckett LA, Gucalp R, Haigentz M, Bathini VG, Wen H, Zhou K, Pasquinelli PB, Gajavelli S, Sreedhara M, Xie X, Lara P, Gandara DR, Perez-Soler R. Randomized Phase 2 Trial of Pharmacodynamic Separation of Pemetrexed and Intercalated Erlotinib Versus Pemetrexed Alone for Advanced Nonsquamous, Non-small-cell Lung Cancer. Clin Lung Cancer. 2017 01; 18(1):60-67. PMID: 27919627.
      View in: PubMed
    18. Kirschbaum MH, Frankel P, Synold TW, Zain J, Claxton D, Tuscano J, Newman EM, Gandara DR, Lara P. A phase II study of vascular endothelial growth factor trap (Aflibercept, NSC 724770) in patients with myelodysplastic syndrome: a California Cancer Consortium Study. Br J Haematol. 2018 02; 180(3):445-448. PMID: 27650362.
      View in: PubMed
    19. Daly ME, Lara P. Local Radiation for Extensive Stage Small Cell Lung Cancer: A Step Forward or Running in Place? Clin Lung Cancer. 2016 07; 17(4):237-8. PMID: 27346548.
      View in: PubMed
    20. Yap SA, Yuh LM, Evans CP, Dall'Era MA, Wagenaar RM, Cress R, Lara P. Evolving patterns of care in the management of stage I non-seminomatous germ cell tumors: data from the California Cancer Registry. World J Urol. 2017 Feb; 35(2):277-283. PMID: 27306686.
      View in: PubMed
    21. Chow H, Ghosh PM, deVere White R, Evans CP, Dall'Era MA, Yap SA, Li Y, Beckett LA, Lara P, Pan CX. A phase 2 clinical trial of everolimus plus bicalutamide for castration-resistant prostate cancer. Cancer. 2016 06 15; 122(12):1897-904. PMID: 27019001; PMCID: PMC4892938 [Available on 06/15/17].
    22. Parikh M, Riess J, Lara P. New and emerging developments in extensive-stage small cell lung cancer therapeutics. Curr Opin Oncol. 2016 Mar; 28(2):97-103. PMID: 26844984.
      View in: PubMed
    23. Lara P, Moon J, Hesketh PJ, Redman MW, Williamson SK, Akerley WL, Hirsch FR, Mack PC, Gandara DR. SWOG S0709: Randomized Phase II Trial of Erlotinib versus Erlotinib Plus Carboplatin/Paclitaxel in Patients with Advanced Non-Small Cell Lung Cancer and Impaired Performance Status as Selected by a Serum Proteomics Assay. J Thorac Oncol. 2016 Mar; 11(3):420-5. PMID: 26725184; PMCID: PMC4775366 [Available on 03/01/17].
    24. Lara P, Moon J, Redman MW, Semrad TJ, Kelly K, Allen J, Gitlitz B, Mack PC, Gandara DR. Disease Control Rate at 8 Weeks Predicts Subsequent Survival in Platinum-Treated Extensive Stage Small-Cell Lung Cancer: Results From the Southwest Oncology Group (SWOG) Database. Clin Lung Cancer. 2016 Mar; 17(2):113-8.e1-2. PMID: 26498504.
      View in: PubMed
    25. Chow H, Edelman MJ, Giaccone G, Ramalingam SS, Quill TA, Bowser AD, Mortimer J, Guerra W, Beckett LA, West HL, Lara P, Gandara DR. Impact of an Interactive On-line Tool on Therapeutic Decision-Making for Patients with Advanced Non-Small-Cell Lung Cancer. J Thorac Oncol. 2015 Oct; 10(10):1421-9. PMID: 25719266.
      View in: PubMed
    26. Quinn DI, Lara P. Renal-Cell Cancer--Targeting an Immune Checkpoint or Multiple Kinases. N Engl J Med. 2015 Nov 05; 373(19):1872-4. PMID: 26406149.
      View in: PubMed
    27. Gandara DR, Lara P, Mack PC. Patient-Derived Xenografts for Investigation of Acquired Resistance in Oncogene-Driven Cancers: Building a Better Mousetrap. J Clin Oncol. 2015 Sep 10; 33(26):2839-40. PMID: 26215942.
      View in: PubMed
    28. Lara P, Longmate J, Mack PC, Kelly K, Socinski MA, Salgia R, Gitlitz B, Li T, Koczywas M, Reckamp KL, Gandara DR. Phase II Study of the AKT Inhibitor MK-2206 plus Erlotinib in Patients with Advanced Non-Small Cell Lung Cancer Who Previously Progressed on Erlotinib. Clin Cancer Res. 2015 Oct 01; 21(19):4321-6. PMID: 26106072; PMCID: PMC4592395 [Available on 10/01/16].
    29. Gandara DR, Hammerman PS, Sos ML, Lara P, Hirsch FR. Squamous cell lung cancer: from tumor genomics to cancer therapeutics. Clin Cancer Res. 2015 May 15; 21(10):2236-43. PMID: 25979930; PMCID: PMC4862209.
    30. Lara P, Gandara DR, Redman MW. Reply to "diminishing role of platinum-sensitivity status in patients with small cell lung cancer". J Thorac Oncol. 2015 May; 10(5):e36. PMID: 25898968.
      View in: PubMed
    31. Gandara DR, Mack PC, Bult C, Li T, Lara P, Riess JW, Astrow SH, Gandour-Edwards R, Cooke DT, Yoneda KY, Moore EH, Pan CX, Burich RA, David EA, Keck JG, Airhart S, Goodwin N, de Vere White RW, Liu ET. Bridging tumor genomics to patient outcomes through an integrated patient-derived xenograft platform. Clin Lung Cancer. 2015 May; 16(3):165-72. PMID: 25838158; PMCID: PMC4586173.
    32. Tomlinson BK, Thomson JA, Bomalaski JS, Diaz M, Akande T, Mahaffey N, Li T, Dutia MP, Kelly K, Gong IY, Semrad T, Gandara DR, Pan CX, Lara P. Phase I Trial of Arginine Deprivation Therapy with ADI-PEG 20 Plus Docetaxel in Patients with Advanced Malignant Solid Tumors. Clin Cancer Res. 2015 Jun 01; 21(11):2480-6. PMID: 25739672; PMCID: PMC4452427.
    33. Pugashetti N, Yap SA, Lara P, Gandour-Edwards R, Dall'Era MA. Metastatic signet-ring cell carcinoma of the urinary bladder: A novel management approach to a rare tumour. Can Urol Assoc J. 2015 Mar-Apr; 9(3-4):E204-7. PMID: 26085880; PMCID: PMC4455640.
    34. Lara P, Moon J, Redman MW, Semrad TJ, Kelly K, Allen JW, Gitlitz BJ, Mack PC, Gandara DR. Relevance of platinum-sensitivity status in relapsed/refractory extensive-stage small-cell lung cancer in the modern era: a patient-level analysis of southwest oncology group trials. J Thorac Oncol. 2015 Jan; 10(1):110-5. PMID: 25490004; PMCID: PMC4320001.
    35. Holland WS, Chinn DC, Lara P, Gandara DR, Mack PC. Effects of AKT inhibition on HGF-mediated erlotinib resistance in non-small cell lung cancer cell lines. J Cancer Res Clin Oncol. 2015 Apr; 141(4):615-26. PMID: 25323938; PMCID: PMC4562434.
    36. Goldkorn A, Ely B, Tangen CM, Tai YC, Xu T, Li H, Twardowski P, Veldhuizen PJ, Agarwal N, Carducci MA, Monk JP, Garzotto M, Mack PC, Lara P, Higano CS, Hussain M, Vogelzang NJ, Thompson IM, Cote RJ, Quinn DI. Circulating tumor cell telomerase activity as a prognostic marker for overall survival in SWOG 0421: a phase III metastatic castration resistant prostate cancer trial. Int J Cancer. 2015 Apr 15; 136(8):1856-62. PMID: 25219358; PMCID: PMC4323674.
    37. Semrad T, Barzi A, Lenz HJ, Hutchins IM, Kim EJ, Gong IY, Tanaka M, Beckett L, Holland W, Burich RA, Snyder-Solis L, Mack P, Lara P. Pharmacodynamic separation of gemcitabine and erlotinib in locally advanced or metastatic pancreatic cancer: therapeutic and biomarker results. Int J Clin Oncol. 2015 Jun; 20(3):518-24. PMID: 25091263; PMCID: PMC4318776.
    38. Evans CP, Lara P. Prostate cancer: Predicting response to androgen receptor signalling inhibition. Nat Rev Urol. 2014 Aug; 11(8):433-5. PMID: 25048863.
      View in: PubMed
    39. de Vere White R, Lara P. Toward a common therapeutic framework in castration-resistant prostate cancer: a model for urologic oncology and medical oncology interaction. Urol Oncol. 2014 May; 32(4):380-2. PMID: 24316022; PMCID: PMC4444361.
    40. Chen MS, Lara P, Dang JH, Paterniti DA, Kelly K. Twenty years post-NIH Revitalization Act: enhancing minority participation in clinical trials (EMPaCT): laying the groundwork for improving minority clinical trial accrual: renewing the case for enhancing minority participation in cancer clinical trials. Cancer. 2014 Apr 01; 120 Suppl 7:1091-6. PMID: 24643646; PMCID: PMC3980490.
    41. Cooke DT, Gandara DR, Goodwin NC, Calhoun RF, Lara P, Mack PC, David EA. Outcomes and efficacy of thoracic surgery biopsy for tumor molecular profiling in patients with advanced lung cancer. J Thorac Cardiovasc Surg. 2014 Jul; 148(1):36-40. PMID: 24746995.
      View in: PubMed
    42. Goldkorn A, Ely B, Quinn DI, Tangen CM, Fink LM, Xu T, Twardowski P, Van Veldhuizen PJ, Agarwal N, Carducci MA, Monk JP, Datar RH, Garzotto M, Mack PC, Lara P, Higano CS, Hussain M, Thompson IM, Cote RJ, Vogelzang NJ. Circulating tumor cell counts are prognostic of overall survival in SWOG S0421: a phase III trial of docetaxel with or without atrasentan for metastatic castration-resistant prostate cancer. J Clin Oncol. 2014 Apr 10; 32(11):1136-42. PMID: 24616308; PMCID: PMC3970171.
    43. Lara P, Ely B, Quinn DI, Mack PC, Tangen C, Gertz E, Twardowski PW, Goldkorn A, Hussain M, Vogelzang NJ, Thompson IM, Van Loan MD. Serum biomarkers of bone metabolism in castration-resistant prostate cancer patients with skeletal metastases: results from SWOG 0421. J Natl Cancer Inst. 2014 Apr; 106(4):dju013. PMID: 24565955; PMCID: PMC3982883.
    44. Riess JW, Lara P. Left behind? Drug discovery in extensive-stage small-cell lung cancer. Clin Lung Cancer. 2014 Mar; 15(2):93-5. PMID: 24529447; PMCID: PMC4184801.
    45. Rosenberg JE, Bambury RM, Van Allen EM, Drabkin HA, Lara P, Harzstark AL, Wagle N, Figlin RA, Smith GW, Garraway LA, Choueiri T, Erlandsson F, Laber DA. A phase II trial of AS1411 (a novel nucleolin-targeted DNA aptamer) in metastatic renal cell carcinoma. Invest New Drugs. 2014 Feb; 32(1):178-87. PMID: 24242861; PMCID: PMC4560460.
    46. Twardowski PW, Mack PC, Lara P. Papillary renal cell carcinoma: current progress and future directions. Clin Genitourin Cancer. 2014 Apr; 12(2):74-9. PMID: 24629521.
      View in: PubMed
    47. Lara P, Evans CP. Dasatinib and docetaxel in advanced prostate cancer. Lancet Oncol. 2013 Dec; 14(13):1248-9. PMID: 24211164.
      View in: PubMed
    48. Gandara DR, Li T, Lara P, Kelly K, Riess JW, Redman MW, Mack PC. Acquired resistance to targeted therapies against oncogene-driven non-small-cell lung cancer: approach to subtyping progressive disease and clinical implications. Clin Lung Cancer. 2014 Jan; 15(1):1-6. PMID: 24176733; PMCID: PMC4586161.
    49. Pai A, Brunson A, Brown M, Pan CX, Lara P. Evolving epidemiologic trends in nonclear cell renal cell cancer: an analysis of the California Cancer Registry. Urology. 2013 Oct; 82(4):840-5. PMID: 24074980.
      View in: PubMed
    50. Ho C, Davies AM, Sangha RS, Lau D, Lara P, Chew HK, Beckett L, Mack PC, Riess JW, Gandara DR. Phase I/II trial of pemetrexed plus nab-paclitaxel in advanced solid tumor patients with emphasis on non-small cell lung cancer. Invest New Drugs. 2013 Dec; 31(6):1587-91. PMID: 24013936; PMCID: PMC4562389.
    51. Kelly K, Chansky K, Mack PC, Lara P, Hirsch FR, Franklin WA, Wozniak AJ, Edelman MJ, Williamson SK, Gandara DR. Chemotherapy outcomes by histologic subtypes of non-small-cell lung cancer: analysis of the southwest oncology group database for antimicrotubule-platinum therapy. Clin Lung Cancer. 2013 Nov; 14(6):627-35. PMID: 23910067; PMCID: PMC4122504.
    52. Quinn DI, Tangen CM, Hussain M, Lara P, Goldkorn A, Moinpour CM, Garzotto MG, Mack PC, Carducci MA, Monk JP, Twardowski PW, Van Veldhuizen PJ, Agarwal N, Higano CS, Vogelzang NJ, Thompson IM. Docetaxel and atrasentan versus docetaxel and placebo for men with advanced castration-resistant prostate cancer (SWOG S0421): a randomised phase 3 trial. Lancet Oncol. 2013 Aug; 14(9):893-900. PMID: 23871417; PMCID: PMC4277263.
    53. Semrad TJ, Eddings C, Dutia MP, Christensen S, Lara P. Phase I study of the combination of temsirolimus and pazopanib in advanced solid tumors. Anticancer Drugs. 2013 Jul; 24(6):636-40. PMID: 23698253; PMCID: PMC4153755.
    54. Maus MK, Mack PC, Astrow SH, Stephens CL, Zeger GD, Grimminger PP, Hsiang JH, Huang E, Li T, Lara P, Danenberg KD, Gandara DR. Histology-related associations of ERCC1, RRM1, and TS biomarkers in patients with non-small-cell lung cancer: implications for therapy. J Thorac Oncol. 2013 May; 8(5):582-6. PMID: 23470290.
      View in: PubMed
    55. Mack PC, Gandara DR, Lara P. Efficacy and toxicity differences in lung cancer populations in the era of clinical trials globalization: the 'common arm' approach. Expert Rev Anticancer Ther. 2012 Dec; 12(12):1591-6. PMID: 23253224.
      View in: PubMed
    56. Smith DC, Smith MR, Sweeney C, Elfiky AA, Logothetis C, Corn PG, Vogelzang NJ, Small EJ, Harzstark AL, Gordon MS, Vaishampayan UN, Haas NB, Spira AI, Lara P, Lin CC, Srinivas S, Sella A, Schöffski P, Scheffold C, Weitzman AL, Hussain M. Cabozantinib in patients with advanced prostate cancer: results of a phase II randomized discontinuation trial. J Clin Oncol. 2013 Feb 01; 31(4):412-9. PMID: 23169517; PMCID: PMC4110249.
    57. Javid SH, Unger JM, Gralow JR, Moinpour CM, Wozniak AJ, Goodwin JW, Lara P, Williams PA, Hutchins LF, Gotay CC, Albain KS. A prospective analysis of the influence of older age on physician and patient decision-making when considering enrollment in breast cancer clinical trials (SWOG S0316). Oncologist. 2012; 17(9):1180-90. PMID: 22723506; PMCID: PMC3448411.
    58. Lin TY, Zhang H, Luo J, Li Y, Gao T, Lara P, de Vere White R, Lam KS, Pan CX. Multifunctional targeting micelle nanocarriers with both imaging and therapeutic potential for bladder cancer. Int J Nanomedicine. 2012; 7:2793-804. PMID: 22745542; PMCID: PMC3383352.
    59. Gandara DR, Li T, Lara P, Mack PC, Kelly K, Miyamoto S, Goodwin N, Beckett L, Redman MW. Algorithm for codevelopment of new drug-predictive biomarker combinations: accounting for inter- and intrapatient tumor heterogeneity. Clin Lung Cancer. 2012 Sep; 13(5):321-5. PMID: 22677432; PMCID: PMC4049356.
    60. Hu B, Lara P, Evans CP. Defining an individualized treatment strategy for metastatic renal cancer. Urol Clin North Am. 2012 May; 39(2):233-49, vii. PMID: 22487765.
      View in: PubMed
    61. Shek D, Tomlinson B, Brown M, Brunson A, Pan CX, Lara P. Epidemiologic trends in renal cell carcinoma in the cytokine and post-cytokine eras: a registry analysis of 28,252 patients. Clin Genitourin Cancer. 2012 Jun; 10(2):93-8. PMID: 22382008.
      View in: PubMed
    62. Chang JS, Lara P, Pan CX. Progress in personalizing chemotherapy for bladder cancer. Adv Urol. 2012; 2012:364919. PMID: 22400017; PMCID: PMC3287014.
    63. Pietanza MC, Lynch TJ, Lara P, Cho J, Yanagihara RH, Vrindavanam N, Chowhan NM, Gadgeel SM, Pennell NA, Funke R, Mitchell B, Wakelee HA, Miller VA. XL647--a multitargeted tyrosine kinase inhibitor: results of a phase II study in subjects with non-small cell lung cancer who have progressed after responding to treatment with either gefitinib or erlotinib. J Thorac Oncol. 2012 Jan; 7(1):219-26. PMID: 22011666.
      View in: PubMed
    64. Sangha R, Davies AM, Lara P, Mack PC, Beckett LA, Hesketh PJ, Lau D, Li T, Perkins N, Gandara DR. Intercalated erlotinib-docetaxel dosing schedules designed to achieve pharmacodynamic separation: results of a phase I/II trial. J Thorac Oncol. 2011 Dec; 6(12):2112-9. PMID: 21892109; PMCID: PMC3219834.
    65. Semrad TJ, Eddings C, Pan CX, Lau DH, Gandara D, Beckett L, Lara P. Feasibility study of intra-patient sorafenib dose-escalation or re-escalation in patients with previously treated advanced solid tumors. Invest New Drugs. 2012 Oct; 30(5):2001-7. PMID: 22015991; PMCID: PMC4131984.
    66. Ramalingam SS, Davies AM, Longmate J, Edelman MJ, Lara P, Vokes EE, Villalona-Calero M, Gitlitz B, Reckamp K, Salgia R, Wright JJ, Belani CP, Gandara DR. Bortezomib for patients with advanced-stage bronchioloalveolar carcinoma: a California Cancer Consortium Phase II study (NCI 7003). J Thorac Oncol. 2011 Oct; 6(10):1741-5. PMID: 21716143; PMCID: PMC3220078.
    67. Lara P, Douillard JY, Nakagawa K, von Pawel J, McKeage MJ, Albert I, Losonczy G, Reck M, Heo DS, Fan X, Fandi A, Scagliotti G. Randomized phase III placebo-controlled trial of carboplatin and paclitaxel with or without the vascular disrupting agent vadimezan (ASA404) in advanced non-small-cell lung cancer. J Clin Oncol. 2011 Aug 01; 29(22):2965-71. PMID: 21709202.
      View in: PubMed
    68. Holland WS, Tepper CG, Pietri JE, Chinn DC, Gandara DR, Mack PC, Lara P. Evaluating rational non-cross-resistant combination therapy in advanced clear cell renal cell carcinoma: combined mTOR and AKT inhibitor therapy. Cancer Chemother Pharmacol. 2012 Jan; 69(1):185-94. PMID: 21644050; PMCID: PMC4562405.
    69. Shek D, Longmate J, Quinn DI, Margolin KA, Twardowski P, Gandara DR, Frankel P, Pan CX, Lara P. A phase II trial of gefitinib and pegylated IFNa in previously treated renal cell carcinoma. Int J Clin Oncol. 2011 Oct; 16(5):494-9. PMID: 21431345.
      View in: PubMed
    70. Chamie K, Kurzrock EA, Evans CP, Litwin MS, Koppie TM, Wootton-Gorges SL, Boone JM, Lara P, Devere White RW. Secondary malignancies among nonseminomatous germ cell tumor cancer survivors. Cancer. 2011 Sep 15; 117(18):4219-30. PMID: 21412759.
      View in: PubMed
    71. Semrad TJ, Gandara DR, Lara P. Enhancing the clinical activity of sorafenib through dose escalation: rationale and current experience. Ther Adv Med Oncol. 2011 Mar; 3(2):95-100. PMID: 21789159; PMCID: PMC3126039.
    72. Rothschild SI, Gautschi O, Lara P, Mack PC, Gandara DR. Biomarkers of DNA repair and related pathways: significance in non-small cell lung cancer. Curr Opin Oncol. 2011 Mar; 23(2):150-7. PMID: 21119513.
      View in: PubMed
    73. Lara P, Longmate J, Reckamp K, Gitlitz B, Argiris A, Ramalingam S, Belani CP, Mack PC, Lau DH, Koczywas M, Wright JJ, Shepherd FA, Leighl N, Gandara DR. Randomized phase II trial of concurrent versus sequential bortezomib plus docetaxel in advanced non-small-cell lung cancer: a California cancer consortium trial. Clin Lung Cancer. 2011 Jan; 12(1):33-7. PMID: 21273177; PMCID: PMC3777729.
    74. Gandara DR, Grimminger P, Mack PC, Lara P, Li T, Danenberg PV, Danenberg KD. Association of epidermal growth factor receptor activating mutations with low ERCC1 gene expression in non-small cell lung cancer. J Thorac Oncol. 2010 Dec; 5(12):1933-8. PMID: 20975603.
      View in: PubMed
    75. Chen AM, Lara P. Medical oncology: Chemoradiotherapy for NSCLC-does a 'standard' exist? Nat Rev Clin Oncol. 2011 Jan; 8(1):5-6. PMID: 21102530.
      View in: PubMed
    76. Suga JM, Nguyen DV, Mohammed SM, Brown M, Calhoun R, Yoneda K, Gandara DR, Lara P. Racial disparities on the use of invasive and noninvasive staging in patients with non-small cell lung cancer. J Thorac Oncol. 2010 Nov; 5(11):1772-8. PMID: 20881638.
      View in: PubMed
    77. Wang S, Zhang H, Malfatti M, de Vere White R, Lara P, Turteltaub K, Henderson P, Pan CX. Gemcitabine causes minimal modulation of carboplatin-DNA monoadduct formation and repair in bladder cancer cells. Chem Res Toxicol. 2010 Nov 15; 23(11):1653-5. PMID: 21028869; PMCID: PMC2987236.
    78. Li T, Christensen SD, Frankel PH, Margolin KA, Agarwala SS, Luu T, Mack PC, Lara P, Gandara DR. A phase II study of cell cycle inhibitor UCN-01 in patients with metastatic melanoma: a California Cancer Consortium trial. Invest New Drugs. 2012 Apr; 30(2):741-8. PMID: 20967484; PMCID: PMC3277821.
    79. Zhang H, Aina OH, Lam KS, de Vere White R, Evans C, Henderson P, Lara P, Wang X, Bassuk JA, Pan CX. Identification of a bladder cancer-specific ligand using a combinatorial chemistry approach. Urol Oncol. 2012 Sep; 30(5):635-45. PMID: 20888272; PMCID: PMC4572726.
    80. Lara P, Chansky K, Shibata T, Fukuda H, Tamura T, Crowley J, Redman MW, Natale R, Saijo N, Gandara DR. Common arm comparative outcomes analysis of phase 3 trials of cisplatin + irinotecan versus cisplatin + etoposide in extensive stage small cell lung cancer: final patient-level results from Japan Clinical Oncology Group 9511 and Southwest Oncology Group 0124. Cancer. 2010 Dec 15; 116(24):5710-5. PMID: 20737417; PMCID: PMC2994945.
    81. Twardowski P, Stadler WM, Frankel P, Lara P, Ruel C, Chatta G, Heath E, Quinn DI, Gandara DR. Phase II study of Aflibercept (VEGF-Trap) in patients with recurrent or metastatic urothelial cancer, a California Cancer Consortium Trial. Urology. 2010 Oct; 76(4):923-6. PMID: 20646741; PMCID: PMC2952720.
    82. Dorff TB, Goldman B, Pinski JK, Mack PC, Lara P, Van Veldhuizen PJ, Quinn DI, Vogelzang NJ, Thompson IM, Hussain MH. Clinical and correlative results of SWOG S0354: a phase II trial of CNTO328 (siltuximab), a monoclonal antibody against interleukin-6, in chemotherapy-pretreated patients with castration-resistant prostate cancer. Clin Cancer Res. 2010 Jun 01; 16(11):3028-34. PMID: 20484019; PMCID: PMC2898710.
    83. Gandara DR, Mack PC, Li T, Lara P, Herbst RS. [Evolving treatment algorithms for advanced non-small-cell lung cancer: 2009 looking toward 2012]. Zhongguo Fei Ai Za Zhi. 2010 Mar; 13(3):238-41. PMID: 20681067.
      View in: PubMed
    84. Li T, Lara P, Mack PC, Perez-Soler R, Gandara DR. Intercalation of erlotinib and pemetrexed in the treatment of non-small cell lung cancer. Curr Drug Targets. 2010 Jan; 11(1):85-94. PMID: 19839922.
      View in: PubMed
    85. Mack PC, Holland WS, Burich RA, Sangha R, Solis LJ, Li Y, Beckett LA, Lara P, Davies AM, Gandara DR. EGFR mutations detected in plasma are associated with patient outcomes in erlotinib plus docetaxel-treated non-small cell lung cancer. J Thorac Oncol. 2009 Dec; 4(12):1466-72. PMID: 19884861.
      View in: PubMed
    86. Gordon MS, Hussey M, Nagle RB, Lara P, Mack PC, Dutcher J, Samlowski W, Clark JI, Quinn DI, Pan CX, Crawford D. Phase II study of erlotinib in patients with locally advanced or metastatic papillary histology renal cell cancer: SWOG S0317. J Clin Oncol. 2009 Dec 01; 27(34):5788-93. PMID: 19884559; PMCID: PMC2793000.
    87. Gandara DR, Mack PC, Li T, Lara P, Herbst RS. Evolving treatment algorithms for advanced non-small-cell lung cancer: 2009 looking toward 2012. Clin Lung Cancer. 2009 Nov; 10(6):392-4. PMID: 19900855.
      View in: PubMed
    88. Van Veldhuizen PJ, Hussey M, Lara P, Mack PC, Gandour-Edwards R, Clark JI, Lange MK, Crawford DE. A phase ii study of gemcitabine and capecitabine in patients with advanced renal cell cancer: Southwest Oncology Group Study S0312. Am J Clin Oncol. 2009 Oct; 32(5):453-9. PMID: 19487915; PMCID: PMC3394591.
    89. Sangha R, Lara P, Adjei AA, Baas P, Choy H, Gaspar LE, Goss G, Saijo N, Schiller JH, Vokes EE, Gandara DR. Cooperative group research endeavors in small-cell lung cancer: current and future directions. Clin Lung Cancer. 2009 Sep; 10(5):322-30. PMID: 19808190.
      View in: PubMed
    90. Davies AM, Ho C, Beckett L, Lau D, Scudder SA, Lara P, Perkins N, Gandara DR. Intermittent erlotinib in combination with pemetrexed: phase I schedules designed to achieve pharmacodynamic separation. J Thorac Oncol. 2009 Jul; 4(7):862-8. PMID: 19494788.
      View in: PubMed
    91. Gandara DR, Kawaguchi T, Crowley J, Moon J, Furuse K, Kawahara M, Teramukai S, Ohe Y, Kubota K, Williamson SK, Gautschi O, Lenz HJ, McLeod HL, Lara P, Coltman CA, Fukuoka M, Saijo N, Fukushima M, Mack PC. Japanese-US common-arm analysis of paclitaxel plus carboplatin in advanced non-small-cell lung cancer: a model for assessing population-related pharmacogenomics. J Clin Oncol. 2009 Jul 20; 27(21):3540-6. PMID: 19470925; PMCID: PMC2717760.
    92. Gandara DR, Lara P, Mack P, Scagliotti G. Individualizing therapy for non-small-cell lung cancer: a paradigm shift from empiric to integrated decision-making. Clin Lung Cancer. 2009 May; 10(3):148-50. PMID: 19443333.
      View in: PubMed
    93. deVere White RW, Lara P, Goldman B, Tangen CM, Smith DC, Wood DP, Hussain MH, Crawford ED. A sequential treatment approach to myoinvasive urothelial cancer: a phase II Southwest Oncology Group trial (S0219). J Urol. 2009 Jun; 181(6):2476-80; discussion 2480-1. PMID: 19371909.
      View in: PubMed
    94. Le QT, Moon J, Redman M, Williamson SK, Lara P, Goldberg Z, Gaspar LE, Crowley JJ, Moore DF, Gandara DR. Phase II study of tirapazamine, cisplatin, and etoposide and concurrent thoracic radiotherapy for limited-stage small-cell lung cancer: SWOG 0222. J Clin Oncol. 2009 Jun 20; 27(18):3014-9. PMID: 19364954; PMCID: PMC2702233.
    95. Lara P, Natale R, Crowley J, Lenz HJ, Redman MW, Carleton JE, Jett J, Langer CJ, Kuebler JP, Dakhil SR, Chansky K, Gandara DR. Phase III trial of irinotecan/cisplatin compared with etoposide/cisplatin in extensive-stage small-cell lung cancer: clinical and pharmacogenomic results from SWOG S0124. J Clin Oncol. 2009 May 20; 27(15):2530-5. PMID: 19349543; PMCID: PMC2684855.
    96. Purnell PR, Mack PC, Tepper CG, Evans CP, Green TP, Gumerlock PH, Lara P, Gandara DR, Kung HJ, Gautschi O. The Src inhibitor AZD0530 blocks invasion and may act as a radiosensitizer in lung cancer cells. J Thorac Oncol. 2009 Apr; 4(4):448-54. PMID: 19240653; PMCID: PMC2716757.
    97. Sangha R, Lara P, Mack PC, Gandara DR. Beyond antiepidermal growth factor receptors and antiangiogenesis strategies for nonsmall cell lung cancer: exploring a new frontier. Curr Opin Oncol. 2009 Mar; 21(2):116-23. PMID: 19532012.
      View in: PubMed
    98. Lara P, Longmate J, Evans CP, Quinn DI, Twardowski P, Chatta G, Posadas E, Stadler W, Gandara DR. A phase II trial of the Src-kinase inhibitor AZD0530 in patients with advanced castration-resistant prostate cancer: a California Cancer Consortium study. Anticancer Drugs. 2009 Mar; 20(3):179-84. PMID: 19396016; PMCID: PMC3225398.
    99. Chen G, Huynh M, Fehrenbacher L, West H, Lara P, Yavorkovsky LL, Russin M, Goldstein D, Gandara D, Lau D. Phase II trial of irinotecan and carboplatin for extensive or relapsed small-cell lung cancer. J Clin Oncol. 2009 Mar 20; 27(9):1401-4. PMID: 19204194; PMCID: PMC2668551.
    100. Davies AM, Chansky K, Lara P, Gumerlock PH, Crowley J, Albain KS, Vogel SJ, Gandara DR. Bortezomib plus gemcitabine/carboplatin as first-line treatment of advanced non-small cell lung cancer: a phase II Southwest Oncology Group Study (S0339). J Thorac Oncol. 2009 Jan; 4(1):87-92. PMID: 19096312; PMCID: PMC3024911.
    101. Cheung E, Pinski J, Dorff T, Groshen S, Quinn DI, Reynolds CP, Maurer BJ, Lara P, Tsao-Wei DD, Twardowski P, Chatta G, McNamara M, Gandara DR. Oral fenretinide in biochemically recurrent prostate cancer: a California cancer consortium phase II trial. Clin Genitourin Cancer. 2009 Jan; 7(1):43-50. PMID: 19213668.
      View in: PubMed
    102. Lara P, Tangen CM, Conlon SJ, Flanigan RC, Crawford ED. Predictors of survival of advanced renal cell carcinoma: long-term results from Southwest Oncology Group Trial S8949. J Urol. 2009 Feb; 181(2):512-6; discussion 516-7. PMID: 19100570; PMCID: PMC3394523.
    103. Levandovsky M, Harvey D, Lara P, Wun T. Thrombotic thrombocytopenic purpura-hemolytic uremic syndrome (TTP-HUS): a 24-year clinical experience with 178 patients. J Hematol Oncol. 2008 Dec 01; 1:23. PMID: 19046460; PMCID: PMC2613392.
    104. Gandara DR, Lara P, Natale R, Belani C. Progress in small-cell lung cancer: the lowest common denominator. J Clin Oncol. 2008 Sep 10; 26(26):4236-8. PMID: 18779609.
      View in: PubMed
    105. Mack PC, Redman MW, Chansky K, Williamson SK, Farneth NC, Lara P, Franklin WA, Le QT, Crowley JJ, Gandara DR. Lower osteopontin plasma levels are associated with superior outcomes in advanced non-small-cell lung cancer patients receiving platinum-based chemotherapy: SWOG Study S0003. J Clin Oncol. 2008 Oct 10; 26(29):4771-6. PMID: 18779603; PMCID: PMC2653139.
    106. Beer TM, Goldman B, Synold TW, Ryan CW, Vasist LS, Van Veldhuizen PJ, Dakhil SR, Lara P, Drelichman A, Hussain MH, Crawford ED. Southwest Oncology Group phase II study of ispinesib in androgen-independent prostate cancer previously treated with taxanes. Clin Genitourin Cancer. 2008 Sep; 6(2):103-9. PMID: 18824433.
      View in: PubMed
    107. Chee KG, Nguyen DV, Brown M, Gandara DR, Wun T, Lara P. Positron emission tomography and improved survival in patients with lung cancer: the Will Rogers phenomenon revisited. Arch Intern Med. 2008 Jul 28; 168(14):1541-9. PMID: 18663166.
      View in: PubMed
    108. Lau D, Johl J, Huynh M, Davies A, Tanaka M, Lara P, Gandara D. Population-based phase I trial of irinotecan and epirubicin. Am J Clin Oncol. 2008 Jun; 31(3):226-30. PMID: 18525299.
      View in: PubMed
    109. Lara P, Ramalingam SS. Monoclonal antibodies versus tyrosine kinase inhibitors concurrent with chemotherapy in non-small-cell lung cancer: exploring divergent results. Clin Lung Cancer. 2008 May; 9(3):141-3. PMID: 18621622.
      View in: PubMed
    110. Ramírez ML, Nelson EC, Devere White RW, Lara P, Evans CP. Current applications for prostate-specific antigen doubling time. Eur Urol. 2008 Aug; 54(2):291-300. PMID: 18439749.
      View in: PubMed
    111. Gautschi O, Tepper CG, Purnell PR, Izumiya Y, Evans CP, Green TP, Desprez PY, Lara P, Gandara DR, Mack PC, Kung HJ. Regulation of Id1 expression by SRC: implications for targeting of the bone morphogenetic protein pathway in cancer. Cancer Res. 2008 Apr 01; 68(7):2250-8. PMID: 18381431.
      View in: PubMed
    112. Gautschi O, Heighway J, Mack PC, Purnell PR, Lara P, Gandara DR. Aurora kinases as anticancer drug targets. Clin Cancer Res. 2008 Mar 15; 14(6):1639-48. PMID: 18347165.
      View in: PubMed
    113. Lara P, Redman MW, Kelly K, Edelman MJ, Williamson SK, Crowley JJ, Gandara DR. Disease control rate at 8 weeks predicts clinical benefit in advanced non-small-cell lung cancer: results from Southwest Oncology Group randomized trials. J Clin Oncol. 2008 Jan 20; 26(3):463-7. PMID: 18202421.
      View in: PubMed
    114. Davies AM, Ruel C, Lara P, Lau DH, Gumerlock PH, Bold R, Shibata S, Lenz HJ, Schenkein DP, Gandara DR. The proteasome inhibitor bortezomib in combination with gemcitabine and carboplatin in advanced non-small cell lung cancer: a California Cancer Consortium Phase I study. J Thorac Oncol. 2008 Jan; 3(1):68-74. PMID: 18166843.
      View in: PubMed
    115. Sangha R, Lara P, Mack P, Gandara DR. Targeted therapies in non-small-cell lung cancer: a paradigm in evolution. Clin Lung Cancer. 2008; 9 Suppl 3:S90-1. PMID: 19419929.
      View in: PubMed
    116. Umutyan A, Chiechi C, Beckett LA, Paterniti DA, Turrell C, Gandara DR, Davis SW, Wun T, Chen MS, Lara P. Overcoming barriers to cancer clinical trial accrual: impact of a mass media campaign. Cancer. 2008 Jan 01; 112(1):212-9. PMID: 18008353.
      View in: PubMed
    117. Davies AM, Ho C, Metzger AS, Beckett LA, Christensen S, Tanaka M, Lara P, Lau DH, Gandara DR. Phase I study of two different schedules of bortezomib and pemetrexed in advanced solid tumors with emphasis on non-small cell lung cancer. J Thorac Oncol. 2007 Dec; 2(12):1112-6. PMID: 18090584.
      View in: PubMed
    118. Chee KG, Longmate J, Quinn DI, Chatta G, Pinski J, Twardowski P, Pan CX, Cambio A, Evans CP, Gandara DR, Lara P. The AKT inhibitor perifosine in biochemically recurrent prostate cancer: a phase II California/Pittsburgh cancer consortium trial. Clin Genitourin Cancer. 2007 Dec; 5(7):433-7. PMID: 18272025.
      View in: PubMed
    119. Mahaffey CM, Davies AM, Lara P, Pryde B, Holland W, Mack PC, Gumerlock PH, Gandara DR. Schedule-dependent apoptosis in K-ras mutant non-small-cell lung cancer cell lines treated with docetaxel and erlotinib: rationale for pharmacodynamic separation. Clin Lung Cancer. 2007 Nov; 8(9):548-53. PMID: 18186959.
      View in: PubMed
    120. Vinall RL, Hwa K, Ghosh P, Pan CX, Lara P, de Vere White RW. Combination treatment of prostate cancer cell lines with bioactive soy isoflavones and perifosine causes increased growth arrest and/or apoptosis. Clin Cancer Res. 2007 Oct 15; 13(20):6204-16. PMID: 17947488.
      View in: PubMed
    121. Ryan CW, Goldman BH, Lara P, Mack PC, Beer TM, Tangen CM, Lemmon D, Pan CX, Drabkin HA, Crawford ED. Sorafenib with interferon alfa-2b as first-line treatment of advanced renal carcinoma: a phase II study of the Southwest Oncology Group. J Clin Oncol. 2007 Aug 01; 25(22):3296-301. PMID: 17664477.
      View in: PubMed
    122. Davies AM, Lara P, Mack PC, Gandara DR. Incorporating bortezomib into the treatment of lung cancer. Clin Cancer Res. 2007 Aug 01; 13(15 Pt 2):s4647-51. PMID: 17671158.
      View in: PubMed
    123. Vansteenkiste J, Lara P, Le Chevalier T, Breton JL, Bonomi P, Sandler AB, Socinski MA, Delbaldo C, McHenry B, Lebwohl D, Peck R, Edelman MJ, Edelman M. Phase II clinical trial of the epothilone B analog, ixabepilone, in patients with non small-cell lung cancer whose tumors have failed first-line platinum-based chemotherapy. J Clin Oncol. 2007 Aug 10; 25(23):3448-55. PMID: 17606973.
      View in: PubMed
    124. Lara P, Davies AM. Optimizing targeted therapy in patients with lung cancer with a performance status of 2. Clin Lung Cancer. 2007 Jul; 8(7):410-1. PMID: 17681092.
      View in: PubMed
    125. Nelson EC, Evans CP, Pan CX, Lara P. Prostate cancer and markers of bone metabolism: diagnostic, prognostic, and therapeutic implications. World J Urol. 2007 Aug; 25(4):393-9. PMID: 17562051.
      View in: PubMed
    126. Hussain MH, MacVicar GR, Petrylak DP, Dunn RL, Vaishampayan U, Lara P, Chatta GS, Nanus DM, Glode LM, Trump DL, Chen H, Smith DC. Trastuzumab, paclitaxel, carboplatin, and gemcitabine in advanced human epidermal growth factor receptor-2/neu-positive urothelial carcinoma: results of a multicenter phase II National Cancer Institute trial. J Clin Oncol. 2007 Jun 01; 25(16):2218-24. PMID: 17538166.
      View in: PubMed
    127. Margolin K, Synold TW, Lara P, Frankel P, Lacey SF, Quinn DI, Baratta T, Dutcher JP, Xi B, Diamond DJ, Gandara DR. Oblimersen and alpha-interferon in metastatic renal cancer: a phase II study of the California Cancer Consortium. J Cancer Res Clin Oncol. 2007 Oct; 133(10):705-11. PMID: 17508219.
      View in: PubMed
    128. Davies AM, Ho C, Hesketh PJ, Beckett LA, Lara P, Lau DH, Gandara DR. Erlotinib and vinorelbine in advanced malignant solid tumors: a phase I study. Invest New Drugs. 2007 Aug; 25(4):351-5. PMID: 17440682.
      View in: PubMed
    129. Nelson EC, Evans CP, Lara P. Renal cell carcinoma: current status and emerging therapies. Cancer Treat Rev. 2007 May; 33(3):299-313. PMID: 17329029.
      View in: PubMed
    130. Nelson EC, Cambio AJ, Yang JC, Lara P, Evans CP. Biologic agents as adjunctive therapy for prostate cancer: a rationale for use with androgen deprivation. Nat Clin Pract Urol. 2007 Feb; 4(2):82-94. PMID: 17287869.
      View in: PubMed
    131. Gandara DR, Davies AM, Gautschi O, Mack PC, Lau DH, Lara P, Hirsch FR. Epidermal growth factor receptor inhibitors plus chemotherapy in non-small-cell lung cancer: biologic rationale for combination strategies. Clin Lung Cancer. 2007 Feb; 8 Suppl 2:S61-7. PMID: 17382026.
      View in: PubMed
    132. Motzer RJ, Nichols CJ, Margolin KA, Bacik J, Richardson PG, Vogelzang NJ, Bajorin DF, Lara P, Einhorn L, Mazumdar M, Bosl GJ. Phase III randomized trial of conventional-dose chemotherapy with or without high-dose chemotherapy and autologous hematopoietic stem-cell rescue as first-line treatment for patients with poor-prognosis metastatic germ cell tumors. J Clin Oncol. 2007 Jan 20; 25(3):247-56. PMID: 17235042.
      View in: PubMed
    133. Pan CX, Zhang H, Lara P, Cheng L. Small-cell carcinoma of the urinary bladder: diagnosis and management. Expert Rev Anticancer Ther. 2006 Dec; 6(12):1707-13. PMID: 17181484.
      View in: PubMed
    134. Lara P, Chansky K, Davies AM, Franklin WA, Gumerlock PH, Guaglianone PP, Atkins JN, Farneth N, Mack PC, Crowley JJ, Gandara DR. Bortezomib (PS-341) in relapsed or refractory extensive stage small cell lung cancer: a Southwest Oncology Group phase II trial (S0327). J Thorac Oncol. 2006 Nov; 1(9):996-1001. PMID: 17409985.
      View in: PubMed
    135. Gandara DR, Chansky K, Albain KS, Gaspar LE, Lara P, Kelly K, Crowley J, Livingston R. Long-term survival with concurrent chemoradiation therapy followed by consolidation docetaxel in stage IIIB non-small-cell lung cancer: a phase II Southwest Oncology Group Study (S9504). Clin Lung Cancer. 2006 Sep; 8(2):116-21. PMID: 17026812.
      View in: PubMed
    136. Gautschi O, Mack PC, Davies AM, Lara P, Gandara DR. Aurora kinase inhibitors: a new class of targeted drugs in cancer. Clin Lung Cancer. 2006 Sep; 8(2):93-8. PMID: 17026809.
      View in: PubMed
    137. Lara P, de Vere White R. Accrual issues in genitourinary cancer clinical trials. Urol Oncol. 2006 Sep-Oct; 24(5):379-83. PMID: 16962485.
      View in: PubMed
    138. Quality of life and pain in advanced stage prostate cancer: results of a Southwest Oncology Group randomized trial comparing docetaxel and estramustine to mitoxantrone and prednisone. J Clin Oncol. 2006 Jun 20; 24(18):2828-35. PMID: 16782921.
      View in: PubMed
    139. Ho C, Davies AM, Lara P, Gandara DR. Second-line treatment for advanced-stage non-small-cell lung cancer: current and future options. Clin Lung Cancer. 2006 May; 7 Suppl 4:S118-25. PMID: 16764752.
      View in: PubMed
    140. Davies AM, Ho C, Lara P, Mack P, Gumerlock PH, Gandara DR. Pharmacodynamic separation of epidermal growth factor receptor tyrosine kinase inhibitors and chemotherapy in non-small-cell lung cancer. Clin Lung Cancer. 2006 May; 7(6):385-8. PMID: 16800963.
      View in: PubMed
    141. Petrylak DP, Ankerst DP, Jiang CS, Tangen CM, Hussain MH, Lara P, Jones JA, Taplin ME, Burch PA, Kohli M, Benson MC, Small EJ, Raghavan D, Crawford ED. Evaluation of prostate-specific antigen declines for surrogacy in patients treated on SWOG 99-16. J Natl Cancer Inst. 2006 Apr 19; 98(8):516-21. PMID: 16622120.
      View in: PubMed
    142. Lara P, Stadler WM, Longmate J, Quinn DI, Wexler J, Van Loan M, Twardowski P, Gumerlock PH, Vogelzang NJ, Vokes EE, Lenz HJ, Doroshow JH, Gandara DR. A randomized phase II trial of the matrix metalloproteinase inhibitor BMS-275291 in hormone-refractory prostate cancer patients with bone metastases. Clin Cancer Res. 2006 Mar 01; 12(5):1556-63. PMID: 16533781.
      View in: PubMed
    143. Lara P, Gandara DR, Natale RB. Randomized phase III trial of cisplatin/irinotecan versus cisplatin/etoposide in patients with extensive-stage small-cell lung cancer. Clin Lung Cancer. 2006 Mar; 7(5):353-6. PMID: 16640809.
      View in: PubMed
    144. Lara P, Koczywas M, Quinn DI, Lenz HJ, Davies AM, Lau DH, Gumerlock PH, Longmate J, Doroshow JH, Schenkein D, Kashala O, Gandara DR. Bortezomib plus docetaxel in advanced non-small cell lung cancer and other solid tumors: a phase I California Cancer Consortium trial. J Thorac Oncol. 2006 Feb; 1(2):126-34. PMID: 17409841.
      View in: PubMed
    145. Lara P. Molecular selection for therapy of patients with non-small-cell lung cancer and impaired performance status: has the time come? Clin Lung Cancer. 2006 Jan; 7(4):232-4. PMID: 16512975.
      View in: PubMed
    146. Lara P, Paterniti DA, Chiechi C, Turrell C, Morain C, Horan N, Montell L, Gonzalez J, Davis S, Umutyan A, Martel CL, Gandara DR, Wun T, Beckett LA, Chen MS. Evaluation of factors affecting awareness of and willingness to participate in cancer clinical trials. J Clin Oncol. 2005 Dec 20; 23(36):9282-9. PMID: 16361626.
      View in: PubMed
    147. Williamson SK, Crowley JJ, Lara P, McCoy J, Lau DH, Tucker RW, Mills GM, Gandara DR. Phase III trial of paclitaxel plus carboplatin with or without tirapazamine in advanced non-small-cell lung cancer: Southwest Oncology Group Trial S0003. J Clin Oncol. 2005 Dec 20; 23(36):9097-104. PMID: 16361616.
      View in: PubMed
    148. Paterniti DA, Chen MS, Chiechi C, Beckett LA, Horan N, Turrell C, Smith L, Morain C, Montell L, Luis Gonzalez J, Davis S, Lara P. Asian Americans and cancer clinical trials: a mixed-methods approach to understanding awareness and experience. Cancer. 2005 Dec 15; 104(12 Suppl):3015-24. PMID: 16247795; PMCID: PMC1810970.
    149. Rigas JR, Lara P. Current perspectives on treatment strategies for locally advanced, unresectable stage III non-small cell lung cancer. Lung Cancer. 2005 Dec; 50S2:S17-S24. PMID: 16551518.
      View in: PubMed
    150. Rigas JR, Lara P. Current perspectives on treatment strategies for locally advanced, unresectable stage III non-small cell lung cancer. Lung Cancer. 2005 Dec; 50 Suppl 2:S17-24. PMID: 16557670.
      View in: PubMed
    151. Gandara DR, Vallières E, Gaspar LE, Kelly K, Albain KS, Herbst RS, Lara P, Mack P, Gumerlock PH, Crowley JJ. Therapeutic strategies for combined-modality therapy of locally advanced non-small-cell lung cancer: rationale for consolidation docetaxel therapy. Clin Lung Cancer. 2005 Dec; 7 Suppl 3:S93-7. PMID: 16384543.
      View in: PubMed
    152. Hussain M, Tangen CM, Lara P, Vaishampayan UN, Petrylak DP, Colevas AD, Sakr WA, Crawford ED. Ixabepilone (epothilone B analogue BMS-247550) is active in chemotherapy-naive patients with hormone-refractory prostate cancer: a Southwest Oncology Group trial S0111. J Clin Oncol. 2005 Dec 01; 23(34):8724-9. PMID: 16314632.
      View in: PubMed
    153. Davies AM, Lara P, Mack PC, Gumerlock PH, Bold RJ, Gandara DR. Bortezomib-based combinations in the treatment of non-small-cell lung cancer. Clin Lung Cancer. 2005 Oct; 7 Suppl 2:S59-63. PMID: 16250929.
      View in: PubMed
    154. Lara P, Bold RJ, Mack PC, Davies AM, Gumerlock PH, Gandara DR. Proteasome inhibition in small-cell lung cancer: preclinical rationale and clinical applications. Clin Lung Cancer. 2005 Oct; 7 Suppl 2:S67-71. PMID: 16250931.
      View in: PubMed
    155. Ok JH, Cambio A, Lara P, Evans CP. Is the use of anything but MVAC justified in the evidence-based medicine era? Curr Opin Urol. 2005 Sep; 15(5):312-4. PMID: 16093854.
      View in: PubMed
    156. Chee KG, Cambio A, Lara P. Recent developments in advanced urothelial cancer. Curr Opin Urol. 2005 Sep; 15(5):342-9. PMID: 16093860.
      View in: PubMed
    157. Richman CM, Denardo SJ, O'Donnell RT, Yuan A, Shen S, Goldstein DS, Tuscano JM, Wun T, Chew HK, Lara P, Kukis DL, Natarajan A, Meares CF, Lamborn KR, DeNardo GL. High-dose radioimmunotherapy combined with fixed, low-dose paclitaxel in metastatic prostate and breast cancer by using a MUC-1 monoclonal antibody, m170, linked to indium-111/yttrium-90 via a cathepsin cleavable linker with cyclosporine to prevent human anti-mouse antibody. Clin Cancer Res. 2005 Aug 15; 11(16):5920-7. PMID: 16115934.
      View in: PubMed
    158. Mortenson MM, Schlieman MG, Virudachalam S, Lara P, Gandara DG, Davies AM, Bold RJ. Reduction in BCL-2 levels by 26S proteasome inhibition with bortezomib is associated with induction of apoptosis in small cell lung cancer. Lung Cancer. 2005 Aug; 49(2):163-70. PMID: 16022909.
      View in: PubMed
    159. Gandara D, Narayan S, Lara P, Goldberg Z, Davies A, Lau DH, Mack P, Gumerlock P, Vijayakumar S. Integration of novel therapeutics into combined modality therapy of locally advanced non-small cell lung cancer. Clin Cancer Res. 2005 Jul 01; 11(13 Pt 2):5057s-5062s. PMID: 16000614.
      View in: PubMed
    160. Lara P, Mack PC, Synold T, Frankel P, Longmate J, Gumerlock PH, Doroshow JH, Gandara DR. The cyclin-dependent kinase inhibitor UCN-01 plus cisplatin in advanced solid tumors: a California cancer consortium phase I pharmacokinetic and molecular correlative trial. Clin Cancer Res. 2005 Jun 15; 11(12):4444-50. PMID: 15958629.
      View in: PubMed
    161. Van Veldhuizen PJ, Faulkner JR, Lara P, Gumerlock PH, Goodwin JW, Dakhil SR, Gross HM, Flanigan RC, Crawford ED. A phase II study of flavopiridol in patients with advanced renal cell carcinoma: results of Southwest Oncology Group Trial 0109. Cancer Chemother Pharmacol. 2005 Jul; 56(1):39-45. PMID: 15791454.
      View in: PubMed
    162. Lara P, Law LY, Wright JJ, Frankel P, Twardowski P, Lenz HJ, Lau DH, Kawaguchi T, Gumerlock PH, Doroshow JH, Gandara DR. Intermittent dosing of the farnesyl transferase inhibitor tipifarnib (R115777) in advanced malignant solid tumors: a phase I California Cancer Consortium Trial. Anticancer Drugs. 2005 Mar; 16(3):317-21. PMID: 15711184.
      View in: PubMed
    163. Lara P, Twardowski P, Quinn DI. Angiogenesis-targeted therapies in prostate cancer. Clin Prostate Cancer. 2004 Dec; 3(3):165-73. PMID: 15636683.
      View in: PubMed
    164. Petrylak DP, Tangen CM, Hussain MH, Lara P, Jones JA, Taplin ME, Burch PA, Berry D, Moinpour C, Kohli M, Benson MC, Small EJ, Raghavan D, Crawford ED. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med. 2004 Oct 07; 351(15):1513-20. PMID: 15470214.
      View in: PubMed
    165. Lara P, Gumerlock PH, Mack PC, Lau DH, Gandour-Edwards R, Edelman MJ, Albain KS, Law LY, Longmate J, Frankel P, Reddy GP, Israel V, Doroshow JH, Gandara DR. Gemcitabine in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy: a phase II California cancer consortium trial. Clin Lung Cancer. 2004 Sep; 6(2):102-7. PMID: 15476595.
      View in: PubMed
    166. Martel CL, Li Y, Beckett L, Chew H, Christensen S, Davies A, Lam KS, Lau DH, Meyers FJ, O'donnell RT, Richman C, Scudder S, Tanaka M, Tuscano J, Welborn J, Wun T, Gandara DR, Lara P. An evaluation of barriers to accrual in the era of legislation requiring insurance coverage of cancer clinical trial costs in California. Cancer J. 2004 Sep-Oct; 10(5):294-300. PMID: 15530258.
      View in: PubMed
    167. Lara P, Chee KG, Longmate J, Ruel C, Meyers FJ, Gray CR, Edwards RG, Gumerlock PH, Twardowski P, Doroshow JH, Gandara DR. Trastuzumab plus docetaxel in HER-2/neu-positive prostate carcinoma: final results from the California Cancer Consortium Screening and Phase II Trial. Cancer. 2004 May 15; 100(10):2125-31. PMID: 15139054.
      View in: PubMed
    168. Davies AM, Lara P, Lau DH, Gandara DR. Treatment of extensive small cell lung cancer. Hematol Oncol Clin North Am. 2004 Apr; 18(2):373-85. PMID: 15094177.
      View in: PubMed
    169. Davies AM, Mack PC, Lara P, Lau DH, Danenberg K, Gumerlock PH, Gandara DR. Predictive molecular markers: has the time come for routine use in lung cancer? J Natl Compr Canc Netw. 2004 Mar; 2(2):125-31. PMID: 19777702.
      View in: PubMed
    170. Liu G, Gandara DR, Lara P, Raghavan D, Doroshow JH, Twardowski P, Kantoff P, Oh W, Kim K, Wilding G. A Phase II trial of flavopiridol (NSC #649890) in patients with previously untreated metastatic androgen-independent prostate cancer. Clin Cancer Res. 2004 Feb 01; 10(3):924-8. PMID: 14871968.
      View in: PubMed
    171. Lara P, Davies AM, Mack PC, Mortenson MM, Bold RJ, Gumerlock PH, Gandara DR. Proteasome inhibition with PS-341 (bortezomib) in lung cancer therapy. Semin Oncol. 2004 Feb; 31(1 Suppl 1):40-6. PMID: 14981579.
      View in: PubMed
    172. Lara P, Laptalo L, Longmate J, Lau DH, Gandour-Edwards R, Gumerlock PH, Doroshow JH, Gandara DR. Trastuzumab plus docetaxel in HER2/neu-positive non-small-cell lung cancer: a California Cancer Consortium screening and phase II trial. Clin Lung Cancer. 2004 Jan; 5(4):231-6. PMID: 14967075.
      View in: PubMed
    173. Lara P, Meyers FJ, Law LY, Dawson NA, Houston J, Lauder I, Edelman MJ. Platinum-free combination chemotherapy in patients with advanced or metastatic transitional cell carcinoma. Cancer. 2004 Jan 01; 100(1):82-8. PMID: 14692027.
      View in: PubMed
    174. Roberts PF, Straznicka M, Lara P, Lau DH, Follette DM, Gandara DR, Benfield JR. Resection of multifocal non-small cell lung cancer when the bronchioloalveolar subtype is involved. J Thorac Cardiovasc Surg. 2003 Nov; 126(5):1597-602. PMID: 14666039.
      View in: PubMed
    175. Lara P, Quinn DI, Margolin K, Meyers FJ, Longmate J, Frankel P, Mack PC, Turrell C, Valk P, Rao J, Buckley P, Wun T, Gosselin R, Galvin I, Gumerlock PH, Lenz HJ, Doroshow JH, Gandara DR. SU5416 plus interferon alpha in advanced renal cell carcinoma: a phase II California Cancer Consortium Study with biological and imaging correlates of angiogenesis inhibition. Clin Cancer Res. 2003 Oct 15; 9(13):4772-81. PMID: 14581348.
      View in: PubMed
    176. Lara P, Frankel P, Mack PC, Gumerlock PH, Galvin I, Martel CL, Longmate J, Doroshow JH, Lenz HJ, Lau DH, Gandara DR. Tirapazamine plus carboplatin and paclitaxel in advanced malignant solid tumors: a california cancer consortium phase I and molecular correlative study. Clin Cancer Res. 2003 Oct 01; 9(12):4356-62. PMID: 14555506.
      View in: PubMed
    177. DeNardo SJ, DeNardo GL, Yuan A, Richman CM, O'Donnell RT, Lara P, Kukis DL, Natarajan A, Lamborn KR, Jacobs F, Siantar CL. Enhanced therapeutic index of radioimmunotherapy (RIT) in prostate cancer patients: comparison of radiation dosimetry for 1,4,7,10-tetraazacyclododecane-N,N',N",N"'-tetraacetic acid (DOTA)-peptide versus 2IT-DOTA monoclonal antibody linkage for RIT. Clin Cancer Res. 2003 Sep 01; 9(10 Pt 2):3938S-44S. PMID: 14506192.
      View in: PubMed
    178. Mack PC, Davies AM, Lara P, Gumerlock PH, Gandara DR. Integration of the proteasome inhibitor PS-341 (Velcade) into the therapeutic approach to lung cancer. Lung Cancer. 2003 Aug; 41 Suppl 1:S89-96. PMID: 12867067.
      View in: PubMed
    179. Wild CA, Wang SE, Gandara DR, Lara P, Meyers FJ, Tanaka M, Houston J, Lauder J, Lau DH. Population-based maximum tolerated dose of irinotecan and carboplatin. Oncology (Williston Park). 2003 Jul; 17(7 Suppl 7):11-6. PMID: 12886868.
      View in: PubMed
    180. Martel CL, Gumerlock PH, Meyers FJ, Lara P. Current strategies in the management of hormone refractory prostate cancer. Cancer Treat Rev. 2003 Jun; 29(3):171-87. PMID: 12787712.
      View in: PubMed
    181. Gandara DR, Chansky K, Albain KS, Leigh BR, Gaspar LE, Lara P, Burris H, Gumerlock P, Kuebler JP, Bearden JD, Crowley J, Livingston R. Consolidation docetaxel after concurrent chemoradiotherapy in stage IIIB non-small-cell lung cancer: phase II Southwest Oncology Group Study S9504. J Clin Oncol. 2003 May 15; 21(10):2004-10. PMID: 12743155.
      View in: PubMed
    182. Davies AM, Lara P, Mack PC, Gandara DR. Docetaxel in non-small cell lung cancer: a review. Expert Opin Pharmacother. 2003 Apr; 4(4):553-65. PMID: 12667118.
      View in: PubMed
    183. Mack PC, Gandara DR, Lau AH, Lara P, Edelman MJ, Gumerlock PH. Cell cycle-dependent potentiation of cisplatin by UCN-01 in non-small-cell lung carcinoma. Cancer Chemother Pharmacol. 2003 Apr; 51(4):337-48. PMID: 12721762.
      View in: PubMed
    184. Martel CL, Lara P. Renal cell carcinoma: current status and future directions. Crit Rev Oncol Hematol. 2003 Feb; 45(2):177-90. PMID: 12604128.
      View in: PubMed
    185. Davies AM, Gandara DR, Lara P, Mack PC, Lau DH, Gumerlock PH. Antisense oligonucleotides in the treatment of non-small-cell lung cancer. Clin Lung Cancer. 2003 Jan; 4 Suppl 2:S68-73. PMID: 14720340.
      View in: PubMed
    186. Lara P. Adjuvant therapy in completely resected malignant thymoma. Cancer Invest. 2003; 21(5):815-6. PMID: 14628439.
      View in: PubMed
    187. Lim N, Lara P, Lau DH, Edelman MJ, Tanaka M, al-Jazayrly G, Houston J, Lauder I, Gandara DR. Phase I trial of gemcitabine and paclitaxel in advanced solid tumors. Cancer Invest. 2003; 21(1):7-13. PMID: 12643004.
      View in: PubMed
    188. Gandour-Edwards R, Lara P, Folkins AK, LaSalle JM, Beckett L, Li Y, Meyers FJ, DeVere-White R. Does HER2/neu expression provide prognostic information in patients with advanced urothelial carcinoma? Cancer. 2002 Sep 01; 95(5):1009-15. PMID: 12209684.
      View in: PubMed
    189. Wang SE, Lara P, Lee-Ow A, Reed J, Wang LR, Palmer P, Tuscano JM, Richman CM, Beckett L, Wun T. Acetaminophen and diphenhydramine as premedication for platelet transfusions: a prospective randomized double-blind placebo-controlled trial. Am J Hematol. 2002 Jul; 70(3):191-4. PMID: 12111764.
      View in: PubMed
    190. Davies A, Gandara DR, Lara P, Goldberg Z, Roberts P, Lau D. Current and future therapeutic approaches in locally advanced (stage III) non-small cell lung cancer. Semin Oncol. 2002 Jun; 29(3 Suppl 12):10-6. PMID: 12170446.
      View in: PubMed
    191. Lara P, Meyers FJ, Gray CR, Edwards RG, Gumerlock PH, Kauderer C, Tichauer G, Twardowski P, Doroshow JH, Gandara DR. HER-2/neu is overexpressed infrequently in patients with prostate carcinoma. Results from the California Cancer Consortium Screening Trial. Cancer. 2002 May 15; 94(10):2584-9. PMID: 12173324.
      View in: PubMed
    192. Lara P, Goldberg Z, Davies A, Lau DH, Gandara DR. Concurrent chemoradiation strategies in the management of unresectable stage III non-small-cell lung cancer. Clin Lung Cancer. 2002 May; 3 Suppl 2:S42-8. PMID: 14720347.
      View in: PubMed
    193. Lara P, Lau DH, Gandara DR. Non-small-cell lung cancer progression after first-line chemotherapy. Curr Treat Options Oncol. 2002 Feb; 3(1):53-8. PMID: 12057087.
      View in: PubMed
    194. Gandara DR, Lara P, Goldberg Z, Le QT, Mack PC, Lau DH, Gumerlock PH. Tirapazamine: prototype for a novel class of therapeutic agents targeting tumor hypoxia. Semin Oncol. 2002 Feb; 29(1 Suppl 4):102-9. PMID: 11894020.
      View in: PubMed
    195. Quock J, Dea G, Tanaka M, Gandara D, Lara P, Lau D. Premedication strategy for weekly paclitaxel. Cancer Invest. 2002; 20(5-6):666-72. PMID: 12197222.
      View in: PubMed